Lilly(US:LLY)2025-12-02 16:32Financial Data and Key Metrics Changes - The company has seen significant progress across its portfolio over the last few years, particularly in expanding access to obesity treatments and self-pay options [6][9] - The anticipated launch of Orforglipron in early Q2 2026 is expected to enhance the company's offerings in obesity treatment [10][15] Business Line Data and Key Metrics Changes - LillyDirect has been a key component in expanding access, with close to 45% of new starts occurring through this platform [9][26] - The company has announced a partnership with Walmart to improve prescription pickup convenience for patients [9] Market Data and Key Metrics Changes - The penetration rate for obesity treatments remains in single digits, indicating significant growth potential as coverage expands [13][15] - The agreement with the White House is expected to provide broad access to approximately 80% of the on-label population under Medicare, with a low out-of-pocket cost [18][19] Company Strategy and Development Direction - The company is focusing on treating obesity as a chronic disease and expanding its pipeline and consumer offerings [9][10] - There is a strategic emphasis on increasing employer opt-ins and improving access across various payer segments, including Medicare and Medicaid [20][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges posed by illegal compounding but believes that increasing access through LillyDirect will help combat this issue [36][37] - The company is optimistic about the growth trajectory of its obesity treatments and the potential for Orforglipron to expand the market [15][50] Other Important Information - The company is actively exploring external innovation opportunities, including partnerships in genetic medicine and AI, to enhance its pipeline [53][54] - The company is committed to improving global health and addressing unmet medical needs in various therapeutic areas [32][40] Q&A Session Summary Question: How does the company rank its priorities looking to 2026 from a commercial perspective? - The company is prioritizing the treatment of obesity as a chronic disease, expanding its pipeline, and enhancing consumer offerings through platforms like LillyDirect [9][10] Question: How does the company segment the Tirzepatide commercial in the U.S. with broader access to the Orforglipron launch? - Management sees Zepbound becoming a standard of care while Orforglipron will provide an effective oral option for patients not ready for injectables [11][12] Question: What is the expected impact of the Medicare and Medicaid rollout on access to treatments? - Medicare is expected to start coverage as early as April 1, with gradual ramp-up, while Medicaid improvements are anticipated over a longer period [18][19] Question: How does LillyDirect play a role in broader access? - LillyDirect provides transparency on pricing and facilitates access to information and disease education, which is crucial for patients navigating obesity treatment [24][26] Question: What are the company's priorities regarding new therapeutic areas? - The company is focusing on cardiometabolic health, inflammation, and brain health, with a significant emphasis on expanding access to obesity treatments [39][40]